It is essential to understand that caplacizumab only prevents the interaction between platelets and the ultra-large vWF multimers and does not treat the underlying cause of TTP; hence, the concurrent use of TPE and rituximab to remove or decrease the production of antibodies, respectively. This evidence concerns the gene VWF and thrombotic thrombocytopenic purpura.